These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 20038760

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Insights for practice: where mechanism of action meets patient management.
    Lisak RP, Korngold S.
    Neurology; 2010 Jan 05; 74 Suppl 1():S70-3. PubMed ID: 20038766
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Glatiramer acetate treatment of multiple sclerosis: an immunological perspective.
    Racke MK, Lovett-Racke AE.
    J Immunol; 2011 Feb 15; 186(4):1887-90. PubMed ID: 21289312
    [Abstract] [Full Text] [Related]

  • 6. Monoclonal antibodies in MS: mechanisms of action.
    Bielekova B, Becker BL.
    Neurology; 2010 Jan 05; 74 Suppl 1(Suppl 1):S31-40. PubMed ID: 20038761
    [Abstract] [Full Text] [Related]

  • 7. Mechanisms of mitoxantrone in multiple sclerosis--what is known?
    Neuhaus O, Kieseier BC, Hartung HP.
    J Neurol Sci; 2004 Aug 15; 223(1):25-7. PubMed ID: 15261556
    [Abstract] [Full Text] [Related]

  • 8. Recent insights into the mechanism of action of glatiramer acetate.
    Kala M, Miravalle A, Vollmer T.
    J Neuroimmunol; 2011 Jun 15; 235(1-2):9-17. PubMed ID: 21402415
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Glatiramer acetate: mechanisms of action in multiple sclerosis.
    Schrempf W, Ziemssen T.
    Autoimmun Rev; 2007 Aug 15; 6(7):469-75. PubMed ID: 17643935
    [Abstract] [Full Text] [Related]

  • 12. Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action.
    Farina C, Weber MS, Meinl E, Wekerle H, Hohlfeld R.
    Lancet Neurol; 2005 Sep 15; 4(9):567-75. PubMed ID: 16109363
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Long-term effects of glatiramer acetate in multiple sclerosis].
    Brochet B.
    Rev Neurol (Paris); 2008 Nov 15; 164(11):917-26. PubMed ID: 18790510
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. CD30 antigen and multiple sclerosis: CD30, an important costimulatory molecule and marker of a regulatory subpopulation of dendritic cells, is involved in the maintenance of the physiological balance between TH1/TH2 immune responses and tolerance. The role of IFNbeta-1a in the treatment of multiple sclerosis.
    Pellegrini P, Totaro R, Contasta I, Berghella AM, Carolei A, Adorno D.
    Neuroimmunomodulation; 2005 Nov 15; 12(4):220-34. PubMed ID: 15990453
    [Abstract] [Full Text] [Related]

  • 17. Blocking effects of serum reactive antibodies induced by glatiramer acetate treatment in multiple sclerosis.
    Salama HH, Hong J, Zang YC, El-Mongui A, Zhang J.
    Brain; 2003 Dec 15; 126(Pt 12):2638-47. PubMed ID: 12937077
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Glatiramer acetate in multiple sclerosis.
    Mezzapesa DM, Rovaris M, Filippi M.
    Expert Rev Neurother; 2005 Jul 15; 5(4):451-8. PubMed ID: 16026228
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.
    Cadavid D, Wolansky LJ, Skurnick J, Lincoln J, Cheriyan J, Szczepanowski K, Kamin SS, Pachner AR, Halper J, Cook SD.
    Neurology; 2009 Jun 09; 72(23):1976-83. PubMed ID: 19279320
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.